The Myeloma Minutes

Episode

• 037 From Patient to Author: Jonathan Gluck’s Myeloma Story 11.06.2026 48mnt

  Author Jonathan Gluck shares his deeply personal experience of living with myeloma, reflecting on diagnosis, uncertainty, treatment, resilience and what it means to build a life alongside cancer.📌Key Takeaways: How do you live with uncertainty? Jonathan shares the lessons myeloma taught him.  A diagnosis can change your life - but it doesn’t have to define it.  One patient’s story of resilience, perspective and finding hope in unexpected places.Find Jonathan's book here: Amazon UKFor extra content and more resources, please visit our website: https://www.themyelomaminutes.com/We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/The Myeloma UK InfoLine is: 0800 980 3332This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concernsABOUT YOUR HOSTSDr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 036 Infection and Myeloma - Staying Safe Without Stopping Life 29.05.2026 41mnt

  This episode explores why people with myeloma are more vulnerable to infection, how treatments affect immunity, and the practical steps patients and carers can take to stay well.📌Key Takeaways:Myeloma and its treatments can weaken the immune system - but the risk changes over time. Fever, coughs or feeling “not quite right” should never be ignored - early treatment matters.From vaccines to exercise and preventative antibiotics, small steps can make a big difference. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/The Myeloma UK InfoLine is: 0800 980 3332This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTSDr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity. Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 035 Blood Clots and Myeloma - What Every Patient Should Know 14.05.2026 27mnt

  This episode explains why people with myeloma are at higher risk of blood clots, how blood thinners help, and the warning signs patients and carers should never ignore. 📌Key Takeaways: Myeloma and some myeloma treatments can increase the risk of dangerous blood clots. Simple steps like staying hydrated, keeping mobile and taking blood thinners correctly really matter. Leg swelling, chest pain or sudden breathlessness should never be ignored : Fast treatment saves lives. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 034 Pain in Myeloma - Understanding It and Taking Back Control 01.05.2026 38mnt

  This episode explores why pain happens in myeloma, how it affects daily life, and the many ways it can be managed - from painkillers to specialist support. 📌Key Takeaways: Myeloma pain is common - but it can almost always be improved with the right approach. Pain relief isn’t just tablets - treatments, radiotherapy and targeted procedures all play a role. Uncontrolled pain affects everything - so speak up early and often to get the help you need. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 033 MRD Explained: How Much Myeloma Is Really Left 09.04.2026 29mnt

  This episode explains minimal residual disease (MRD) - what it is, how it’s measured, and how it could shape more personalised myeloma treatment in the future. 📌Key Takeaways: Even when blood tests look ‘normal’, tiny amounts of myeloma can still remain - MRD helps find it. Reaching MRD negativity is a powerful sign - it often means longer, deeper remission. In the future, MRD could decide when to stop, reduce or restart treatment - but we’re not quite there yet. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 032 What Do My Blood Results Mean? - A Myeloma Guide 26.03.2026 37mnt

  This episode breaks down common blood test results in myeloma, helping patients and carers understand what the numbers mean, what matters most, and when to worry (and when not to). 📌Key Takeaways: Not all ‘red’ results are bad - trends over time matter more than a single number. Three key numbers to watch: haemoglobin, neutrophils and platelets. Blood tests are your roadmap - guiding treatment, safety and how you’re really doing. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 031 Living Young with Myeloma: Treatment, Relapse and a Breakthrough with CAR-T 26.02.2026 42mnt

  Meera shares her powerful 15-year journey with multiple myeloma — from diagnosis during pregnancy to stem cell transplant, maintenance therapy and ultimately CAR-T treatment leading to remission.   📌Key Takeaways: CAR-T can work fast! Mira’s light chains became undetectable within weeks. Relapse doesn’t mean the end of options: new treatments are changing what’s possible. You are not alone: sharing real patient stories helps break the isolation of myeloma. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 030 CAR-T Therapy Explained: A Personalised Treatment for Myeloma 12.02.2026 37mnt

  In this episode Doctors Jam & Sally explain CAR-T cell therapy for myeloma - how it works, what the treatment journey looks like, the potential side effects, and why it offers hope for longer treatment-free time. 📌Key Takeaways: Your own immune cells can be re-engineered to find and destroy myeloma - a truly personalised treatment. After CAR-T, many patients can have months or years off regular therapy. It’s powerful and promising - but not everyone can access it yet, and it doesn’t work for all patients. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 029 Belantamab Returns: A New Combination for First Relapse Myeloma 29.01.2026 23mnt

  This episode explains the new NICE-approved combination of belantamab, pomalidomide and dexamethasone for people whose myeloma has relapsed after first-line treatment, including benefits, side effects and how treatment decisions are made. 📌Key Takeaways: This new combination can keep myeloma under control for nearly three years after first relapse. Eye side effects are common but closely monitored, reversible and manageable with dose changes. Patients now have real choice between tablet-based or injection-based combinations after relapse. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 028 Myeloma in 2026 - What's Coming Next and Why It Matters 15.01.2026 31mnt

  This episode looks ahead to 2026, exploring upcoming myeloma treatments, major research advances, and the topics patients and carers most want to understand. 📌Key Takeaways: Powerful new immunotherapy combinations could dramatically change how long treatments work. CAR T-cell therapy and bispecific antibodies are moving closer to earlier use in myeloma care. Living well with myeloma matters more than ever - from infection risk to quality of life. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 027 From Functional Cure to Satsuma sized devices : Myeloma Highlights of the Year (Part 2 of 2) 31.12.2025 27mnt

  Dr Jam Katari and Dr Sally Moore are joined by leading myeloma experts to look back on 2025’s biggest breakthroughs; from functional cures and new treatments to patient-friendly innovations. This is part 2 of a seasonal special, featuring Professor Karthik Ramasamy and Dr. Ceri Bygrave. To hear the first part, please follow this link: Part1 🌟 Three key take-away points from Part 2 Functional cure is no longer just a dream — it’s becoming part of everyday myeloma care. New drugs and smarter treatment combinations are transforming survival and quality of life. Innovation is making treatment easier — even down to a “Satsuma-sized” on-body injection device! For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332   This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 026 From Smouldering to Sci-Fi : Myeloma Highlights of the Year (Part 1 of 2) 18.12.2025 28mnt

  Dr Jam Katari and Dr Sally Moore are joined by leading myeloma experts to look back on 2025’s biggest breakthroughs; from early treatment for smouldering myeloma to cutting-edge CAR-T therapy made inside the body. This is part 1 of a seasonal special, featuring Professor Karthik Ramasamy and Dr. Ceri Bygrave. Please ensure you listen to our second part next week. 🌟 Three key take-away points Early action: Could treating smouldering myeloma stop the disease before it starts? Sharper tools: New genetic tests are redefining what “high-risk” myeloma really means. Future now: “In vivo” CAR-T therapy turns your own body into the treatment factory—real-life medical sci-fi! For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332   This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 025 An Additional New Hope - Understanding GPRC5D Treatment 04.12.2025 33mnt

  This episode introduces Talquetamab - a newly approved bispecific antibody for relapsed myeloma - explaining how it works, who it’s for, and what side effects patients should expect and prepare for. 📌Key Takeaways: Talquetamab is a brand-new treatment targeting GPRC5D - offering another effective option after several previous therapies. Early side effects like fever, blood pressure changes or confusion are monitored closely and are almost always reversible. Taste changes, mouth soreness, skin issues and nail changes are common - but they can usually be managed so patients can stay on the treatment. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 024 From Braces to Bone Regrowth: Modern Spine Care in Myeloma 20.11.2025 52mnt

  Sean Molloy, renown spinal surgeon at the Royal National Orthopaedic Hospital (RNOH) NHS Trust in Stanmore explains how tailored bracing, breakthrough bone healing in myeloma, physiotherapy and minimally invasive vertebroplasty can transform pain, mobility and long-term spinal stability.   📌Key Takeaways: A brace can act like “nature’s own surgery”, guiding powerful myeloma-driven bone regrowth to prevent long-term spinal collapse. The first 12 weeks after diagnosis are critical — the right brace and mobility plan can stop irreversible forward bending (kyphosis). For selected patients, vertebroplasty can provide rapid pain relief, restoring function when a single fracture refuses to settle. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 023 Numbness, Tingling and Treatment: Making Sense of Neuropathy 06.11.2025 35mnt

  Dr Jam & Sally unpack what neuropathy is, why it happens in myeloma treatment, and how patients can recognise, prevent and manage it to protect their quality of life. 📌Key Takeaways: Know the signs early – tingling, numbness or pain shouldn’t be ignored; speak up before symptoms worsen. Treatment can be adjusted – modern dosing and combinations make neuropathy less common and more manageable. You don’t have to live with it – there are effective ways to ease nerve pain and protect your long-term wellbeing. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 022 Remission, Relapse and Reality Understanding the R-Words in Myeloma 23.10.2025 33mnt

  Dr Jam & Sally unpack what remission, relapse and refractory disease truly mean for people living with myeloma — and explore how close we are to talking about cure.   📌Key Takeaways: Remission ≠ cure – myeloma can be controlled for years, even if it never fully disappears. Monitoring matters – blood tests, bone marrow checks and scans together tell the full story. Hope is growing – deeper remissions and new tests mean “functional cure” is now within reach. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 021 Understanding Risk in Myeloma: What Your Genetics Can Tell You 09.10.2025 36mnt

  This episode unpacks the complex world of myeloma genetics - what high and standard risk really mean, how these tests guide treatment, and how future advances could lead to truly personalised care with Sarah Gooding. Sarah is a colleague, and an Honorary Consultant Haematologist, based in Oxford.   📌Key Takeaways: Your myeloma is unique - genetic tests help doctors understand how it may behave and respond to treatment. High-risk myeloma can still respond well to newer, more powerful therapies now being developed. The future lies in personalised treatment - matching the right drug to each patient’s myeloma for the best outcomes. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 020 Myeloma UK at the Heart: Advocacy, Research and Hope 25.09.2025 37mnt

  This episode features Dr Sophie Castell, CEO of Myeloma UK, sharing insights into the charity’s vital work in research, advocacy, patient support, and tackling inequalities in myeloma care.   📌Key Takeaways: Survival rates for myeloma have quadrupled — and living well is now as important as living longer. Myeloma UK drives progress from early diagnosis to survivorship, always keeping patients’ voices central. The new “Knowledge is Power” campaign tackles inequalities, raising awareness in communities most affected. For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/   This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 019 Four Drugs, One Goal - A New Option for Older Myeloma Patients 11.09.2025 34mnt

  Welcome to The Myeloma Minutes.  We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday. This episode explains the newly approved four-drug treatment (Isatuximab, Velcade, Lenalidomide and Dexamethasone) for older people with myeloma who are not eligible for a stem cell transplant. 📌Key Takeaways: This four-drug ‘quadruplet’ can keep myeloma under control for many years — even in older patients. Each drug works differently, combining to give stronger and longer remissions. Side effects like infection, neuropathy or diarrhoea are real — but doses can be tailored to keep patients well. This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
• 018 BCMA Bispecific antibodies - Novel immunotherapies for relapsed myeloma 28.08.2025 40mnt

  Welcome to The Myeloma Minutes.  We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday. This episode explores bispecific antibodies — how they work, the benefits they bring, and the key side effects patients and carers need to know about. 📌Key Takeaways: Bispecific antibodies ‘wake up’ your immune system to fight myeloma — and response rates are higher than ever before. Early side effects (like fever or low blood pressure) usually settle quickly with the right care. Infections are the main long-term risk — but regular antibody infusions and vigilance make treatment much safer. This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.